An update from Lucid Diagnostics ( (LUCD) ) is now available.
On March 4, 2025, Lucid Diagnostics announced a $15.3 million registered direct offering by entering into subscription agreements with accredited investors to sell shares of common stock. The proceeds will be used for working capital and general corporate purposes, with Canaccord Genuity acting as the sole placement agent. This move is expected to bolster Lucid’s financial position and support its operations in the cancer prevention diagnostics industry.
More about Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer. Lucid offers the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer.
YTD Price Performance: 87.34%
Average Trading Volume: 543,595
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $87.83M
Find detailed analytics on LUCD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com